Photocil (Topical) for the Treatment of Vitiligo

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Photocil is a topical drug (cream) that selectively delivers Narrow Band - Ultraviolet B (NB-UVB) therapy when exposed to sunlight. Photocil is intended to help protect users from non-therapeutic Ultraviolet B (UVB) radiation while selectively passing wavelengths of light in the NB-UVB range with peak transmission of 308nm. The aim of the study is to assess the safety and efficacy of Photocil in the treatment of vitiligo.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Applied Biology, Inc.
• Treatments: Sunscreening Agents

Criteria

Inclusion Criteria:

• Diagnosed with vitiligo confirmed by a dermatologist

• Vitiligo lesions affecting at a minimum 5% of the facial, legs, or arms surface area

• Age: 18 to 65

• Participants able to give informed consent

Exclusion Criteria:

• Subject did not respond to prior phototherapy treatment

• Subject completed phototherapy for same lesion(s) in last 6 months

• Subject has previous history of skin cancer

• Subject has previous history of photosensitivity

• Subject has a history of herpes (HSV I or II) outbreaks

• Subject has previous history of autoimmune disease may be excluded at investigator's discretion

• Subject is currently taking of immunosuppressive or photosensitizing drugs

• Subject plans to use antibiotics, anti-fungal, calcineurin inhibitors or other drugs that may cause photosensitivity during the study period. These patients may be excluded at investigator's discretion

• Subject is pregnant or lactating women